USPTO Examiner HINES JANA A - Art Unit 1645

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18851087Hybridoma cell line secreting an ActA monoclonal antibody and use thereofSeptember 2024July 2025Allow1011NoNo
18814445MULTI-ANTIGEN DIAGNOSTIC FOR DETECTING LYME DISEASEAugust 2024January 2026Allow1731YesNo
18737799COMPOSITION FOR INDUCING PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSJune 2024April 2025Abandon1020YesNo
18633805DIETARY SUPPLEMENT COMPOSITION FOR TREATING AND MANAGING ACNEApril 2024September 2024Allow510YesNo
18632343OSTRICH ANTIBODY FOR BACTERIAL INFECTIOUS DISEASESApril 2024October 2025Allow1920NoNo
18600406PRODUCTION OF INDOLE-DERIVED METABOLITES BY SHELF-STABLE COMMUNITIES OF SAFE BACTERIAMarch 2024October 2025Abandon1930YesNo
18438693ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTIONFebruary 2024December 2025Allow2210NoNo
18430254ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDFebruary 2024March 2025Allow1420NoNo
18518117METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTIONNovember 2023May 2025Abandon1820NoNo
18506072COMPOSITIONS AND METHODS FOR DETECTING PROTEASE ACTIVITY IN BIOLOGICAL SYSTEMSNovember 2023April 2025Abandon1710NoNo
18386555ETHYL 2-[9-(2-HYDROXYPYRIDIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10- TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow301NoNo
18469188PHARMACEUTICAL COMPOSITION COMPRISING A PROBIOTIC AND PREBIOTIC TO PREVENT ACQUISITION OF OR TREAT DRUG RESISTANT INFECTIONSSeptember 2023April 2025Abandon1821YesYes
18262969USE OF PHARMACEUTICAL COMPOSITION CONTAINING CHLOROGENIC ACID IN PREPARATION OF MEDICAMENT FOR TREATING PATHOLOGIC JAUNDICEJuly 2023March 2026Abandon3210NoNo
18356890NOVEL STREPTOCOCCUS SALIVARIUS STRAIN HAVING ANTIBACTERIAL, ANTIFUNGAL, ANTI-INFLAMMATORY ACTIVITY AND INHIBITING DENTAL CARIES AND ORAL COMPOSITION COMPRISING THE SAMEJuly 2023September 2025Abandon2611YesNo
18217206FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNEJune 2023May 2025Abandon2311NoNo
18265426MICROORGANISM WITH HIGH TRIPEPTIDE PRODUCTIVITY AND USE THEREOFJune 2023March 2026Allow3310NoNo
18139626Anti-PfRH5 Antibodies and Antigen-Binding Fragments ThereofApril 2023May 2024Allow1300NoNo
18033221LATERAL FLOW ASSAY FOR RAPID DETECTION OF PATHOGENS IN SAMPLESApril 2023January 2026Abandon3301NoNo
18129936ANTIBODY DETECTION TEST STRIP OF INTEGRATING PRIMARY SCREENING AND DIAGNOSIS OF BOVINE BRUCELLOSISApril 2023December 2025Allow3310NoNo
18295211True human antibody specific for interleukin 1 alphaApril 2023November 2025Allow3100NoNo
18130005ANTIBODY DETECTION TEST STRIP OF INTEGRATING PRIMARY SCREENING AND DIAGNOSIS OF SHEEP BRUCELLOSISApril 2023January 2026Allow3410NoNo
18194406DIAGNOSING AND TREATING CHRONIC KIDNEY DISEASE IN A FELINEMarch 2023March 2026Abandon3611NoNo
18192505USE OF KLK5 ANTAGONISTS FOR THE TREATMENT OF A DISEASEMarch 2023November 2024Abandon2001NoNo
18182055COMPOSITIONS AND METHODS FOR THE INDUCTION OF CD8+ T-CELLSMarch 2023October 2024Allow2030YesNo
18179190METHODS AND COMPOSITIONS RELATING TO ASSESSMENT FOR INFERTILITYMarch 2023January 2026Abandon3410NoNo
18018178MICROBIOME MEDIATED INDUCTION OF IMMUNE TOLERANCE AND RESOLUTION OF INFLAMMATIONJanuary 2023December 2025Abandon3510NoNo
18097887IMMUNOLOGICAL DETECTION METHOD AND KIT FOR MYCOPLASMA PNEUMONIAEJanuary 2023October 2025Abandon3331YesNo
18149612PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIESJanuary 2023July 2024Abandon1810NoNo
18068725HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSDecember 2022July 2025Allow3121NoNo
18074884MULTIVALENT PNEUMOCOCCAL VACCINE COMPOSITIONS COMPRISING POLYSACCHARIDE-PROTEIN CONJUGATESDecember 2022February 2026Abandon3911NoNo
17997635RAPID LATERAL FLOW ASSAY FOR VIBRIO DETECTIONOctober 2022March 2026Abandon4111NoNo
18049993METHODS AND COMPOSITIONS FOR DETECTING FUNGI AND MYCOTOXINSOctober 2022November 2024Abandon2511NoNo
17952761ASSAYS FOR DETERMINING THE PATHOGENCITY OF TOXOPLASMA INFECTIONSSeptember 2022February 2024Abandon1610NoNo
17934054ALPHA-HEMOLYSIN VARIANTS WITH ALTERED CHARACTERISTICSSeptember 2022March 2024Allow1811YesNo
17860961BLOCKING ELISA KIT FOR DETECTING ANTIBODY TO SWINE ACUTE DIARRHEA SYNDROME CORONAVIRUS N PROTEINJuly 2022February 2026Abandon4311NoNo
17782163SYSTEM AND METHODS FOR MANIPULATION OF THE ORAL MICROBIOME IN MAMMALSJune 2022January 2026Abandon4420YesNo
17739553ANTI-MICROBIAL SEAWEED EXTRACTS, COMPOSITIONS AND USES THEREOFMay 2022January 2024Abandon2110NoNo
17662188PROBIOTIC COMPOSITIONS FOR PRODUCTION OF DOPAMINEMay 2022June 2025Allow3740YesNo
17767994STRAINS AND PROCESSES FOR SINGLE CELL PROTEIN OR BIOMASS PRODUCTIONApril 2022December 2025Allow4421YesNo
17766104HIGH THROUGHPUT, FLUORESCENCE-BASED ESTIMATION OF MONOCLONAL ANTIBODY AGGREGATION WITH DISODIUM 3,3'-{[(E)-1,2-DIPHENYL-1,2-ETHENEDIYL]BIS(4,1-PHENYLENEOXY)}DI (1-PROPANESULFONATE) DYE FOR SUPERIOR SENSITIVITY AND SPECIFICITYApril 2022November 2025Allow4421YesNo
17711081PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSESApril 2022September 2023Allow1710NoNo
17705619MHC CLASS I EPITOPE DELIVERING POLYPEPTIDESMarch 2022February 2024Allow2310NoNo
17702854COMPOSITIONS COMPRISING BACTERIAL STRAINSMarch 2022March 2024Abandon2410NoNo
17699302O-Mannosyltransferase Deficient Filamentous Fungal Cells and Methods of Use ThereofMarch 2022September 2025Abandon4131NoNo
17674932MENINGOCOCCAL B RECOMBINANT VACCINEFebruary 2022March 2024Allow2531YesNo
17633330COMPOSITION FOR INHIBITING REDUCTION OF TESTOSTERONE AND/OR DIHYDROTESTOSTERONEFebruary 2022March 2026Abandon4920NoYes
17591631DIAGNOSTIC METHOD EMPLOYING HNLFebruary 2022January 2024Abandon2311NoNo
17584956BACTERIA ENGINEERED TO TREAT METABOLIC DISEASESJanuary 2022September 2023Allow1910YesNo
17555761METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INDUCING IMMUNE TOLERANCE BY MUCOSAL VACCINATION WITH FC-COUPLED ANTIGENSDecember 2021December 2025Abandon4850NoNo
17595998TETRASACCHARIDES FOR THE DIAGNOSIS, PREVENTION, AND TREATMENT OF MELIOIDOSIS AND GLANDERSDecember 2021March 2025Allow3911NoNo
17534970METHODS AND COMPOSITIONS FOR THE DIAGNOSIS, PROPHYLAXIS AND TREATMENT OF LYME DISEASENovember 2021March 2025Allow4051NoNo
17453529PORTABLE DEVICE AND SYSTEM FOR RAPID DETECTION OF A BACTERIAL CELL IN FLUID SAMPLESNovember 2021September 2025Allow4611NoNo
17608242VAGINAL MICROBIOME MARKERS FOR PREDICTION OF PREVENTION OF PRETERM BIRTH AND OTHER ADVERSE PREGNANCY OUTCOMESNovember 2021April 2025Abandon4201NoNo
17508692TREATMENT OF STAPHYLOCOCCAL DISORDERSOctober 2021April 2024Allow2911NoNo
17498278METHODS FOR TREATING NEPHROTIC SYNDROMEOctober 2021August 2023Allow2210NoNo
17496926METHODS AND ARRAYS FOR TARGET ANALYTE DETECTION AND DETERMINATION OF TARGET ANALYTE CONCENTRATION IN SOLUTIONOctober 2021July 2023Allow2121YesNo
17600743METHOD FOR DETECTING OR MONITORING THE PROGRESSION OF A CHRONIC AUTOIMMUNE DISEASE BY IMMUNOASSAYOctober 2021May 2025Abandon4311NoNo
17481606FLUID HANDLING DEVICESeptember 2021October 2024Abandon3701NoNo
17460658NOVEL PNEUMOCOCCAL VACCINE FORMULATIONSAugust 2021December 2023Abandon2821YesNo
17410908BACTERIAL VACCINE COMPONENTS AND USES THEREOFAugust 2021December 2023Abandon2810NoNo
17403284DIRECT-FED MICROBIALSAugust 2021July 2023Allow2310NoNo
17400441ENGINEERED BOTULINUM NEUROTOXINAugust 2021November 2024Abandon3901NoNo
17397915ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTIONAugust 2021October 2023Allow2611NoNo
17419855BACTERIAL VACCINEJune 2021April 2025Allow4630YesNo
17358086BACTERIAL VACCINE COMPONENTS AND USES THEREOFJune 2021November 2023Abandon2910NoNo
17417364NUCLEIC ACID DETECTIONJune 2021October 2024Abandon4010NoNo
17354161METHOD FOR PREVENTING OR TREATING NOSOCOMIAL PNEUMONIAJune 2021September 2023Abandon2710NoNo
17350690Methods And Compositions For Improved Production Of Fatty Acids And Derivatives ThereofJune 2021October 2024Abandon4010NoNo
17351032Proteins and nucleic acids useful in vaccines targeting Staphylococcus aureusJune 2021February 2026Abandon5641NoNo
17349627ACTIVE SUBSTANCE OF MORCHELLA, ITS USE AND A COMPOSITION THEREOF FOR IMPROVING THE REPRODUCTIVE FUNCTIONJune 2021May 2023Allow2320NoNo
17340532Compositions and Methods Related to Protein A (SpA) VariantsJune 2021November 2023Allow2910NoNo
17297385BIOSENSOR AND METHOD FOR DETECTION OF ANALYTESMay 2021June 2025Allow4911NoNo
17246167COMPOSITIONS AND METHODS FOR DETECTING PROTEASE ACTIVITY IN BIOLOGICAL SYSTEMSApril 2021August 2023Allow2710NoNo
17290385HAFNIA ALVEI FORMULATIONSApril 2021September 2024Abandon4010NoNo
17288909COMPOSITIONS AND METHODS FOR OCHROBACTRUM-MEDIATED PLANT TRANSFORMATIONApril 2021August 2024Abandon4001NoNo
17240433PROBIOTICS FOR USE IN THE PREVENTION OR TREATMENT OF ILLNESS AND/OR SYMPTOMS ASSOCIATED WITH CORONAVIRUSESApril 2021December 2021Allow821YesNo
17288308KITS AND METHODS FOR REAL-TIME MULITPLEX DETECTION AND IDENTIFICATION OF PATHOGENSApril 2021November 2023Abandon3010NoNo
17231526MHC CLASS I EPITOPE DELIVERING POLYPEPTIDESApril 2021December 2021Allow811NoNo
17228382DIAGNOSIS AND TREATMENT OF INVASIVE ASPERGILLOSISApril 2021February 2023Allow2210NoNo
17277857Multiple Heteroresistance to Guide Combination Antibiotic RegimensMarch 2021August 2025Allow5321YesNo
17277592COMPOSITION AGAINST RESISTANT ORGANISMS (MRSA)March 2021November 2023Abandon3210NoNo
17200553COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENTMarch 2021April 2024Allow3711YesNo
17186366Vaccine AdjuvantFebruary 2021May 2024Allow3921NoNo
17178412COMPOSITIONS AND METHODS FOR TREATING AN INFLAMMATORY DISEASE OR DISORDERFebruary 2021July 2023Abandon2911NoNo
17268500RAPID DIAGNOSTICS OF MYCOBACTERIA WITH LECTIN CONJUGATED PARTICLESFebruary 2021November 2022Abandon2120NoNo
17268380METHOD AND COMPOSITION FOR STIMULATING IMMUNE RESPONSEFebruary 2021May 2024Abandon3911NoNo
17149227PEPTIDES AND METHODS FOR THE DETECTION OF LYME DISEASE ANTIBODIESJanuary 2021October 2022Allow2100NoNo
17259457PREVENTING FUNGAL GROWTH IN HONEY BEE COLONIES AND RELATED MATERIALS AND METHODSJanuary 2021March 2023Abandon2610NoNo
17142792VIRB10 FOR VACCINATION AGAINST GRAM NEGATIVE BACTERIAJanuary 2021August 2024Allow4330YesNo
17133589APPARATUS AND METHOD FOR PROCESSING SAMPLES CONTAINING BIOLOGICAL CELLSDecember 2020September 2025Allow5730NoNo
17115827IMMUNIZATION WITH POLYVALENT VENOM VACCINESDecember 2020July 2022Allow1920NoNo
17116353METHODS FOR CONTROLLING PROTEASE PRODUCTIONDecember 2020February 2024Allow3840YesNo
17059918BIOMARKERS FOR THE DIAGNOSIS OF INVASIVE FUNGAL INFECTIONSNovember 2020August 2024Allow4520YesNo
17093133MODIFIED BACTERIA HAVING IMPROVED PHARMACOKINETICS AND TUMOR COLONIZATION ENHANCING ANTITUMOR ACTIVITYNovember 2020June 2023Allow3211YesNo
17053232Methods and Compositions for Treating or Preventing Gut Barrier DysfunctionNovember 2020January 2023Abandon2710NoNo
17051653PROBIOTIC BIFIDOBACTERIUM BREVE STRAIN AND COMPOSITIONS COMPRISING SAID STRAINOctober 2020January 2023Allow2610YesNo
17050666Non-integrative Listeria-based vaccine and method for inducing antitumor immune responseOctober 2020February 2023Allow2811NoNo
17073006USES OF PARASITE MACROPHAGE MIGRATION INHIBITORY FACTORSOctober 2020November 2022Abandon2510NoNo
17071425HUMAN-DERIVED BACTERIA THAT INDUCE PROLIFERATION OR ACCUMULATION OF REGULATORY T CELLSOctober 2020September 2022Allow2311YesNo
17045315Therapeutic Microvesicles of Probiotic BacteriaOctober 2020August 2023Allow3411YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HINES, JANA A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
18
Examiner Affirmed
11
(61.1%)
Examiner Reversed
7
(38.9%)
Reversal Percentile
60.4%
Higher than average

What This Means

With a 38.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
127
Allowed After Appeal Filing
22
(17.3%)
Not Allowed After Appeal Filing
105
(82.7%)
Filing Benefit Percentile
21.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 17.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HINES, JANA A - Prosecution Strategy Guide

Executive Summary

Examiner HINES, JANA A works in Art Unit 1645 and has examined 845 patent applications in our dataset. With an allowance rate of 47.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 35 months.

Allowance Patterns

Examiner HINES, JANA A's allowance rate of 47.5% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HINES, JANA A receive 2.42 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HINES, JANA A is 35 months. This places the examiner in the 38% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.6% benefit to allowance rate for applications examined by HINES, JANA A. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.4% of applications are subsequently allowed. This success rate is in the 15% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 25.4% of cases where such amendments are filed. This entry rate is in the 35% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 69% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 74.6% of appeals filed. This is in the 63% percentile among all examiners. Of these withdrawals, 64.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 76.4% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.1% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 71% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.